 The FDA requested Hemispherx conduct at least one additional controlled trial to demonstrate efficacy in treating CFS.In August 2012, Hemispherx submitted further analyses of the original clinical trial data, but did not submit additional trials for review.Four months later, a committee of the FDA voted 8-5 against approval for rintatolimod, again citing insufficient data.